Patent Board Denies Roxane Request For Inter Partes Review

(February 14, 2017, 2:13 PM EST) -- ALEXANDRIA, Va. — A Novartis AG patent covering a tumor treatment will not be the subject of an upcoming inter partes review (IPR), the Patent Trial and Appeal Board announced Feb....
To view the full article, register now.